Abstract:Abstract In anticancer drug discovery a common strategy is to start with a target-specific screen followed later by characterization of hit compounds in phenotypic cell-based assays. One important advantage of this sequential screening procedure is the feasibility of high throughput compound testing. However, a significant disadvantage of the approach is the fact that due to the sequential nature of the approach, compounds showing promising phenotypic activities, but addressing so far unknown targets will be lost as false-negative compounds. Here we describe a medium throughput screening strategy, where we characterized 360 natural compounds isolated from marine organisms in a parallel target- and phenotypic-driven screening approach. As target-specific read out, we analyzed biochemically the inhibitory potential of the compounds against 16 recombinant protein kinases, known to be relevant targets in different kinds of human tumors. In parallel we determined the impact of the compounds on cell transformation, migration and angiogenesis by analyzing their behavior in soft agar growth, wound healing and three-dimensional endothelial cell sprouting. Furthermore, unspecific toxicity of the compounds was tested via a viability assay with human peripheral mononuclear cells from healthy donors. Examples of identified compounds showing differential inhibitory profiles in the different assays applied will be presented. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C109. Citation Format: Daniel Feger, Holger Weber, Frank Totzke, Marianne Birkle, Oliver Siedentopf, Melanie Müller, Sarah Umber, Wenhan Lin, Peter Proksch, Jan E. Ehlert, Michael H.G. Kubbutat. Discovery of new natural anti-tumoral compounds using a parallel target- and phenotypic-driven screening approach. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C109.

A living cell-based fluorescent reporter for high-throughput screening of anti-tumor drugs

An Isotope-Coded Photocleavable Probe for Quantitative Profiling of Protein O-GlcNAcylation

Specific Turn-On Fluorescent Probe With Aggregation-Induced Emission Characteristics For Sirt1 Modulator Screening And Living-Cell Imaging

Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.

Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening

A GLUT1 inhibitor-based fluorogenic probe for Warburg effect-targeted drug screening and diagnostic imaging of hyperglycolytic cancers

A water-soluble fluorescent probe for the determination of γ-glutamyltransferase activity and its application in tumor imaging

A melatonin-based targetable fluorescent probe for screening of tumor cells and real-time imaging of glutathione fluctuations in tumor cells

Design and application of prodrug fluorescent probes for the detection of ovarian cancer cells and release of anticancer drug

Turn-on Rhodamine Glycoconjugates Enable Real-Time GLUT Activity Monitoring in Live Cells and In Vivo

Investigating NanoLuc-EGFR engineered cell lines for real-time monitoring of EGFR protein dynamics in live cells

Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior

Activity Based High-Throughput Screening for Novel O-GlcNAc Transferase Substrates Using a Dynamic Peptide Microarray

Using β-Lactamase and NanoLuc Luciferase Reporter Gene Assays to Identify Inhibitors of the HIF-1 Signaling Pathway

Debut of a NIR ESIPT-based fluorescent probe with synergistic effects for boosting high-contrast imaging of β-galactosidase in ovarian cancer

Abstract C109: Discovery of New Natural Anti-Tumoral Compounds Using a Parallel Target- and Phenotypic-Driven Screening Approach.

A novel GSH-activable theranostic probe containing kinase inhibitor for synergistic treatment and selective imaging of tumor cells

Identification of Novel Inhibitors of GLUT1 by Virtual Screening and Cell-Based Assays

An Integrated Fluorescent Probe for Ratiometric Detection of Glutathione in the Golgi Apparatus and Activated Organelle-Targeted Therapy

Development of label-free triboelectric nanosensors as screening platforms for anti-tumor drugs

Identification of a Novel GLUT1 Inhibitor with in Vitro and in Vivo Anti-Tumor Activity.